JP2022525545A5 - - Google Patents

Info

Publication number
JP2022525545A5
JP2022525545A5 JP2021556508A JP2021556508A JP2022525545A5 JP 2022525545 A5 JP2022525545 A5 JP 2022525545A5 JP 2021556508 A JP2021556508 A JP 2021556508A JP 2021556508 A JP2021556508 A JP 2021556508A JP 2022525545 A5 JP2022525545 A5 JP 2022525545A5
Authority
JP
Japan
Application number
JP2021556508A
Other languages
Japanese (ja)
Other versions
JP7574206B2 (ja
JP2022525545A (ja
JPWO2020191141A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023532 external-priority patent/WO2020191141A1/en
Publication of JP2022525545A publication Critical patent/JP2022525545A/ja
Publication of JP2022525545A5 publication Critical patent/JP2022525545A5/ja
Publication of JPWO2020191141A5 publication Critical patent/JPWO2020191141A5/ja
Application granted granted Critical
Publication of JP7574206B2 publication Critical patent/JP7574206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556508A 2019-03-20 2020-03-19 ステロール調節エレメント結合転写因子1(srebf1)阻害剤による上昇した脂質レベルの治療 Active JP7574206B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820893P 2019-03-20 2019-03-20
US62/820,893 2019-03-20
US201962879138P 2019-07-26 2019-07-26
US62/879,138 2019-07-26
PCT/US2020/023532 WO2020191141A1 (en) 2019-03-20 2020-03-19 Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors

Publications (4)

Publication Number Publication Date
JP2022525545A JP2022525545A (ja) 2022-05-17
JP2022525545A5 true JP2022525545A5 (https=) 2023-03-22
JPWO2020191141A5 JPWO2020191141A5 (https=) 2023-03-22
JP7574206B2 JP7574206B2 (ja) 2024-10-28

Family

ID=70289471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556508A Active JP7574206B2 (ja) 2019-03-20 2020-03-19 ステロール調節エレメント結合転写因子1(srebf1)阻害剤による上昇した脂質レベルの治療

Country Status (6)

Country Link
US (2) US11504390B2 (https=)
EP (1) EP3942048A1 (https=)
JP (1) JP7574206B2 (https=)
CN (2) CN116889627A (https=)
CA (1) CA3133000A1 (https=)
WO (1) WO2020191141A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116583291A (zh) * 2020-12-14 2023-08-11 雷杰纳荣制药公司 用抑制素亚基βE(INHBE)抑制剂治疗代谢病症和心血管疾病的方法
MX2023007012A (es) 2020-12-14 2023-06-27 Regeneron Pharma Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe).

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5631356A (en) 1992-04-03 1997-05-20 Gist-Brocades, N.V. Selective N-acylation of amino alcohols
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2710337B1 (fr) 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6602710B1 (en) 1998-08-27 2003-08-05 Chugai Seiyaku Kabushiki Kaisha Screening method for SREBP pathway-specific inhibitors
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
HRP20030498A2 (en) 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US20080249040A1 (en) 2001-05-18 2008-10-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA)
AU2002320621A1 (en) 2001-07-20 2003-03-03 Incyte Genomics, Inc. Structural and cytoskeleton-associated proteins
WO2003033656A2 (en) * 2001-10-16 2003-04-24 Exelixis, Inc. MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
US20050014177A1 (en) 2003-05-19 2005-01-20 Koustubh Ranade Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphisms
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
AU2007297388A1 (en) 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. RNAi modulation of scap and therapeutic uses thereof
JP2010053122A (ja) * 2008-07-31 2010-03-11 Hayashibara Biochem Lab Inc 脂質合成阻害剤
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
WO2011087857A2 (en) * 2009-12-22 2011-07-21 The Administrators Of The Tulane Educational Fund Compositions and methods for treating obesity and diabetes
WO2015100257A1 (en) 2013-12-23 2015-07-02 The General Hospital Corporation Methods and assays for determining reduced brca1 pathway function in a cancer cell
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
CN105441454B (zh) 2015-12-23 2018-12-11 北京大学人民医院 Scap基因突变体及其应用
MX2018013499A (es) 2016-05-03 2019-09-11 Lonza Ag Modulacion del metabolismo lipidico para la produccion de proteinas.
WO2019141723A1 (en) * 2018-01-18 2019-07-25 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
AU2019212959A1 (en) 2018-01-29 2020-09-17 Capulus Therapeutics, Llc SREBP inhibitors comprising a 6-membered central ring
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
CN109536610B (zh) * 2018-12-05 2020-10-16 西南大学 Setdb1在调控胆固醇途径中的应用

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)